Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Ocular Surface Disease > Low-level light therapy shows promise in preventing dry eye disease after cataract surgery
  • Ocular Surface Disease

Low-level light therapy shows promise in preventing dry eye disease after cataract surgery

Ophthalmology 360

Low-level light therapy (LLLT) before and after cataract surgery has shown significant promise in preventing dry eye disease (DED) and improving postoperative outcomes, according to results of a clinical trial that demonstrated patients who received LLLT experienced lower levels of ocular discomfort symptoms, better tear film stability, and reduced meibomian gland loss (MGL) compared to the control group.

The trial included 153 patients who were randomly assigned to receive either LLLT or a sham treatment with a power output below 30%. Each participant underwent 2 treatment sessions, 1 approximately a week before cataract surgery and the other a week after the procedure. The outcomes were assessed 30 days post-surgery.

Of the 131 participants who completed the study, those treated with LLLT exhibited significantly lower OSDI scores compared to the control group at both post-treatment time points. The OSDI scores were 7.2±8.8 versus 14.8±13.0 at the first postoperative assessment and 9.0±9.0 versus 18.2±17.9 at the second assessment.

Patients who received LLLT demonstrated higher non-invasive break-up time (NIBUT) values at the second assessment compared to controls (12.5±6.6 vs 9.0±7.8; p=0.007). Notably, unlike the control group, the LLLT-treated patients maintained improved OSDI scores and higher NIBUT values at the second assessment compared to baseline.

The study also noted lower Meiboscore values for meibomian gland loss (MGL) in the LLLT group at the first postoperative assessment (1.59±0.70 vs 1.26±0.69; p=0.008), indicating a positive impact on the function of these vital glands.

Reference
Giannaccare G, Rossi C, Borselli M, et al. Outcomes of low-level light therapy before and after cataract surgery for the prophylaxis of postoperative dry eye: a prospective randomised double-masked controlled clinical trial. Br J Ophthalmol. 2023;bjo-2023-323920. doi: 10.1136/bjo-2023-323920. Epub ahead of print. PMID: 37890879.

Share

Related Content

  • Ocular Surface Disease

Symptomatic MGD shows distinct age-related clinical patterns

  • Ocular Surface Disease

Scleral lenses improve vision and symptoms across ocular surface diseases

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

  • Neurotrophic Keratitis

Novel anterior keratoplasty approach supports healing in refractory ocular surface disease

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon